The Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease (A4) parent trial is a trial of anti-amyloid therapy for prevention of cognitiv decline in 1000 participants who are cognitively healthy, 65-85 years old, and have evidence of amyloid in their brain on flobetapir PET scans. Quality of sleep is important for quality of life ad there is evidence for poorer sleep quality in older persons and in persons at risk of developing Alzheimer's disease. Actigraphy is a low-cost noninvasive method of measuring activity validated for assessing sleep quality, using an accelerometer that is worn like a wristwatch. We propose to add actigraphic assessment of sleep quality in 50 amyloid-positive and 50 amyloid-negative participants who have consented to A4. We hope to assess the effect of anti-amyloid therapy on sleep quality, and the effect of baseline amyloid status on changes in sleep in the placebo and amyloid-negative group.
Sleep is important to quality of life and may also reflect underlying brain processes of aging. We propose to add a low-cost noninvasive measure of sleep (actigraphy) to the Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease Trial (A4) to better understand sleep as an outcome for prevention of functional decline in aging.
|Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358|
|Holingue, Calliope; Wennberg, Alexandra; Berger, Slava et al. (2018) Disturbed sleep and diabetes: A potential nexus of dementia risk. Metabolism 84:85-93|
|Spira, Adam P (2018) Sleep and Health in Older Adulthood: Recent Advances and the Path Forward. J Gerontol A Biol Sci Med Sci 73:357-359|
|Urbanek, Jacek K; Spira, Adam P; Di, Junrui et al. (2018) Epidemiology of objectively measured bedtime and chronotype in US adolescents and adults: NHANES 2003-2006. Chronobiol Int 35:416-434|
|Wanigatunga, Amal A; Simonsick, Eleanor M; Zipunnikov, Vadim et al. (2018) Perceived Fatigability and Objective Physical Activity in Mid- to Late-Life. J Gerontol A Biol Sci Med Sci 73:630-635|
|Spira, Adam P; Ju, Yo-El S (2017) Self-reported sleep and Alzheimer disease CSF biomarkers: A wake-up call. Neurology 89:419-420|
|Spira, Adam P; Gottesman, Rebecca F (2017) Sleep disturbance: an emerging opportunity for Alzheimer's disease prevention? Int Psychogeriatr 29:529-531|
|Wennberg, Alexandra M V; Wu, Mark N; Rosenberg, Paul B et al. (2017) Sleep Disturbance, Cognitive Decline, and Dementia: A Review. Semin Neurol 37:395-406|
|Varma, Vijay R; Dey, Debangan; Leroux, Andrew et al. (2017) Re-evaluating the effect of age on physical activity over the lifespan. Prev Med 101:102-108|
|Kaufmann, Christopher N; Spira, Adam P; Depp, Colin A et al. (2016) Continuing Versus New Prescriptions for Sedative-Hypnotic Medications: United States, 2005-2012. Am J Public Health 106:2019-2025|